Value of serum thyroglobulin measurement in patients operated on for well differentiated thyroid carcinoma

European Journal of Surgery

Volumn 164, Issue 9, 1998, Pages 665-671

  Ruter A ^a   Smeds, S ^a   Lennquist, S ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Follow up; Thyroglobulin; Well differentiated thyroid cancer

Indexed keywords

THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SCHOOL CHILD; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 0031870321     PISSN: 11024151     EISSN: None     Source Type: Journal    
DOI: 10.1080/110241598750005543     Document Type: Article

References (28)

1. Aiello D, Manni A. Thyroglobulin measurement vs iodine 131 total body scan for follow-up of well differentiated thyroid cancer. Arch Intern Med 1990; 150: 437-439.
2. Bayer MKriss J. A solid phase, sandwich-type radioimmunoassay for antithyroglobulin: elimination of false positive results and semiquantitative measurement of antithyroglobulin in the presence of elevated thyroglobulin. J Clin Endocrinol Metabol 1979; 49: 565-571.
3. Bengtsson A, Malmaeus J, Grimelius L, et al. Measurements of nuclear DNA content in thyroid diagnosis. World J Surg 1984; 8: 481-486.
4. Bondeson L, Azavedo E, Bondeson A-G, Caspersson T, Ljungberg O. Nuclear DNA content and behavior of oxyfil thyroid tumors. Cancer 1986; 58: 672-675.
5. Brendel AJ, Lambert B, Guyot M, et al. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med 1990; 16: 35-38.
6. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surg 1988; 104: 947-953.
7. Clark O. TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg 1981; 5: 39-47.
8. De Micco C, Ruf J, Henry J, Carayon P. Thyroglobulin and thyroid peroxidase as thyroid call markers in the diagnosis of thyroid carcinoma. Diagn Oncol 1991; 1: 190-193.
9. Ericsson U-B, Tegler L, Lennquist S, Borup Christensen S, Ståhl E, Thorell J. Serum thyroglobulin in differentiated thyroid carcinoma. Acta Chir Scand 1984; 150: 367-375.
10. Galera-Davidsson H, Bibbo M, Bartels P, Dytch H, Puls J, Wied G. Correlation between automated DNA ploidy measurements of hürtle-cell tumors and their histopathologic clinical features. Anal Quant Cytol Histol 1985; 8: 158-167.
11. Goretzki P, Simon D, Frilling A, et al. Surgical reintervention for differentiated thyroid cancer. Br J Surg 1993; 80: 1009-1012.
12. Grant CS, Hay D. Local recurrence of papillary thyroid carcinoma after unilateral or bilateral thyroidectomy. Wien Klin Woschenschr 1988; 11: 342-346.
13. Grant C, Hay I, Gough I, Bergstralh B, Goellner J, McConahey W. Local recurrence in papillary thyroid carcinoma: Is extent of surgical resection important? Surgery 1988; 104: 954-962.
14. Joensuu H, Klemi P, Eerola E, Tuominen J. Influence of cellular content on survival in differentiated thyroid cancer. Cancer 1986; 58: 2462-2467.
15. Lennquist S, Persliden J, Smeds S. Intraoperative scintigraphy in surgical treatment of thyroid carcinoma: evaluation of a new technique. World J Surg 1986; 10: 711-718.
16. Lennquist S, Persliden J, Smeds S. The value of intraoperative scintigraphy as a routine procedure in thyroid carcinoma. World J Surg 1988; 12: 586-592.
17. Lennquist S. Surgical strategy in thyroid carcinoma: a clinical review. Acta Chir Scand 1986; 152: 321-338.
18. Lennquist S. The thyroid nodule, diagnosis and surgical treatment. Surg Clin North Am 1987; 67: 213-232.
19. Mazzaferri E, Young R. Papillary thyroid carcinoma: a ten year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70: 511-518.
20. Ronga G, Fiorentino A, Pasiero E, et al. Can iodine-131 whole body scan be replaced by thyroglobulin measurement in the postoperative surgical follow-up of differentiated thyroid carcinoma? J Nucl Med 1990; 31: 1766-1771.
21. Rubello D, Casara D, Girelli M, Piccolo M, Busnardo B. Clinical meaning of circulating anti thyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med 1992; 33: 1478-1480.
22. Rubello D, Girelli M, Casara D, Piccolo M, Perin A, Busnardo B. Usefullness of combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with highly differentiated thyroid cancer. J Endocrin Invest 1990; 13: 737-742.
23. Schindler A-M, van Melle G, Evequoz, B, Scazziga B. Prognostic factors in papillary carcinoma of the thyroid. Cancer 1991; 68: 324-330.
24. Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63: 960-967.
25. Spencer C, Wang C. Thyroglobulin measurement, techniques, clinical benefits, and pitfalls. Endocrin Metab Clin North Am 1995; 24: 841-863.
26. Sza'nto' J, Vincze B, Sinkovics I, et al. Postoperative thyroglobulin level determination to follow up patients with highly differentiated thyroid cancer. Oncology 1989; 46: 99-104.
27. Van Herle A, Uller R, Matthews N, Brown J. Radioimmunoassay for measurement of thyroglobulin in human serum. J Clin Invest 1973; 52: 1320-1327.
28. 131I scintigraphy in patients with differentiated thyroid carcinoma. Acta Chir Scand 1988; 154: 141-145.